The article discusses the current situation for myalgic encephalomyelitis (ME) patients in Norway and the health policy implications surrounding their treatment. Health Minister Jan Christian Vestre is advocating for Norway's membership in the EU's health union, amidst proposals from the Norwegian Directorate of Health that suggest not following the World Health Organization's (WHO) ICD-11 classification for ME. Instead, they propose that ME be viewed merely as a subset of long-term fatigue, which keeps the distinction between these disorders unclear.

This proposed mixing of diagnostic groups has raised concerns among ME advocates and medical professionals, as it complicates treatment recommendations and research. The situation is contrasted with Germany, where health authorities recognize ME as a major public health issue, allocating substantial funding for biomedical research into the condition and long COVID. Unlike Norway, Germany's approach reflects a broader acknowledgment of ME/CFS as a neurological disorder with its own diagnostic criteria, as indicated by the WHO.

Ultimately, the article highlights the need for clarity in diagnosing and treating ME patients. By not aligning with WHO classifications, Norway risks further marginalizing these patients and missing out on advancements in research and treatment that are gaining traction internationally. The discussion emphasizes the importance of precise medical definitions to ensure that patients receive the appropriate care they need, while also advocating for changes in the current health policies governing ME treatment in Norway.